Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $4.60 Average Price Target from Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been assigned an average rating of “Moderate Buy” from the five research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $4.60.

Separately, HC Wainwright cut their price objective on shares of Karyopharm Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, June 28th.

Insider Activity

In related news, Director Deepika Pakianathan sold 360,744 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $1.00, for a total transaction of $360,744.00. Following the completion of the transaction, the director now owns 11,209 shares of the company’s stock, valued at $11,209. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 1,275,473 shares of company stock valued at $1,234,542 over the last 90 days. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KPTI. SG Americas Securities LLC increased its position in Karyopharm Therapeutics by 295.0% during the fourth quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock worth $64,000 after purchasing an additional 54,839 shares during the last quarter. Bleakley Financial Group LLC purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at $33,000. Simplicity Solutions LLC purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at $33,000. Los Angeles Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at $339,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Karyopharm Therapeutics by 6.5% in the fourth quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock valued at $1,530,000 after purchasing an additional 108,286 shares during the period. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $0.89 on Monday. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95. The company has a market capitalization of $110.91 million, a PE ratio of -0.70 and a beta of 0.21. The firm’s 50-day moving average is $0.95 and its two-hundred day moving average is $1.12.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.01. The business had revenue of $33.13 million during the quarter, compared to analysts’ expectations of $35.02 million. On average, analysts forecast that Karyopharm Therapeutics will post -1.16 EPS for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).